Two separate human clinical trials have investigated this compound: Ulcerative Colitis Trial Clinical investigation of this compound in patients with ulcerative colitis examined the compounds GI-protective properties properties that are consistent with its gastric origin and documented activity on intestinal permeability barriers in animal models
For anyone using BPC-157 under professional supervision, a chart may help track: Time of administration Route of administration Response over time Side effects or tolerability changes Training, rehab, or symptom patterns Adjusting for Bodyweight and Goals Bodyweight, injury severity, gastrointestinal symptoms, and recovery goals may influence how a clinician evaluates peptide use
Fortunately, a new wave of treatments is on the horizon
,
It came very fast and easy to do
Across the aggregate dosing patterns observed, one protocol that appeared in multi-injury ACL contexts was a 750mcg daily blend of BPC-157 and TB-500 combined